PMID- 16904693
OWN - NLM
STAT- MEDLINE
DCOM- 20061214
LR  - 20061030
IS  - 0022-4804 (Print)
IS  - 0022-4804 (Linking)
VI  - 136
IP  - 1
DP  - 2006 Nov
TI  - Application of bFGF and BDNF to improve angiogenesis and cardiac function.
PG  - 85-91
AB  - BACKGROUND: Brain-derived neurotrophic factor (BDNF) is a survival factor for 
      endothelial cells and expresses in the ischemic myocytes. The purpose of this 
      study was to assess whether the simultaneous application of basic fibroblast 
      growth factor (bFGF) and BDNF incorporating gelatin hydrogels improves 
      angiogenesis and cardiac function in ischemic myocardium compared with bFGF 
      applied alone. MATERIALS AND METHODS: Direct intramyocardial injection of 100 
      microg of bFGF plus 25 microg of BDNF, 100 microg of bFGF, or saline were 
      performed in canine infarct model. Colored microspheres were injected to assess 
      the regional myocardial blood flow. Cardiac function was evaluated by cine 
      magnetic resonance imaging (MRI). Immunohistochemical staining and enzyme linked 
      immunosorbent assay (ELISA) were used to observe the localization and expression 
      of bFGF and BDNF protein, and myocardial microvessel density was assessed by von 
      Willebrand factor staining. RESULTS: Left ventricular ejection fraction (LVEF) 
      was higher in bFGF plus BDNF group than in saline or bFGF group. Blood flow of 
      the peri-infarct region was increased by bFGF plus BDNF treatment. The 
      distribution of bFGF and BDNF-positive cardiomyocytes was similar in three 
      groups. The expression of bFGF and BDNF protein and microvessel density in bFGF 
      plus BDNF group was higher than in the other two groups. CONCLUSIONS: This study 
      indicates that the sustained dual release of bFGF and BDNF incorporating gelatin 
      hydrogels can improve angiogenesis and left ventricular function in the ischemic 
      myocardium compared with bFGF applied alone. bFGF plus BDNF administration may be 
      a promising therapeutic strategy for the treatment of ischemic myocardium.
FAU - Liu, Ying
AU  - Liu Y
AD  - Department of Radiology, Xijing Hospital, Fourth Military Medical University, 
      Xi'an, China.
FAU - Sun, Lijun
AU  - Sun L
FAU - Huan, Yi
AU  - Huan Y
FAU - Zhao, Haitao
AU  - Zhao H
FAU - Deng, Jinglan
AU  - Deng J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060814
PL  - United States
TA  - J Surg Res
JT  - The Journal of surgical research
JID - 0376340
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Hydrogels)
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
SB  - IM
MH  - Animals
MH  - Brain-Derived Neurotrophic Factor/pharmacokinetics/*pharmacology
MH  - Coronary Circulation/drug effects
MH  - Disease Models, Animal
MH  - Dogs
MH  - Drug Therapy, Combination
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Fibroblast Growth Factor 2/pharmacokinetics/*pharmacology
MH  - Hydrogels/pharmacology
MH  - Immunohistochemistry
MH  - Microcirculation/drug effects
MH  - Microspheres
MH  - Myocardial Ischemia/*drug therapy
MH  - Neovascularization, Physiologic/*drug effects
MH  - Stroke Volume/drug effects
MH  - Ventricular Dysfunction, Left/*drug therapy
EDAT- 2006/08/15 09:00
MHDA- 2006/12/15 09:00
CRDT- 2006/08/15 09:00
PHST- 2006/02/08 00:00 [received]
PHST- 2006/04/26 00:00 [revised]
PHST- 2006/04/27 00:00 [accepted]
PHST- 2006/08/15 09:00 [pubmed]
PHST- 2006/12/15 09:00 [medline]
PHST- 2006/08/15 09:00 [entrez]
AID - S0022-4804(06)00242-3 [pii]
AID - 10.1016/j.jss.2006.04.034 [doi]
PST - ppublish
SO  - J Surg Res. 2006 Nov;136(1):85-91. doi: 10.1016/j.jss.2006.04.034. Epub 2006 Aug 
      14.